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ABSTRACT 
Survivin, the smallest member of the inhibitor of apoptosis protein family, plays a central role during 
mitosis and exerts a cytoprotective function. Survivin is highly expressed in most cancer types and 
contributes to multiple facets of carcinogenesis. The molecular mechanisms underlying its highly 
diverse functions need to be extensively explored, which is crucial for rational design of future 
personalized therapeutics. In this study, we have generated an alpaca survivin nanobody (SVVNb8) 
that binds with low nanomolar affinity to its target. When expressed as an intrabody in HeLa cells, 
SVVNb8 faithfully tracks survivin during different phases of mitosis without interfering with survivin 
function. Furthermore, coupling SVVNb8 with a subcellular delocalization tag efficiently redirects 
endogenous survivin towards the nucleus, the cytoplasm, peroxisomes and even to the intermembrane 
space of mitochondria where it presumably interacts with resident mitochondrial survivin. Based on 
our findings, we believe that SVVNb8 is an excellent instrument to further elucidate survivin biology 
and topography, and can serve as a model system to investigate mitochondrial and peroxisomal 
(survivin) protein import. 
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INTRODUCTION 
Survivin (SVV; also known as BIRC5; 16.5 kDa) is the smallest member of the Inhibitor of Apoptosis 
Protein (IAP) family. The protein comprises 142 amino acids organized in two domains: an N-
terminal baculovirus-IAP repeat (BIR) domain, linked to a C-terminal α-helix1. X-ray crystallography 
shows that the protein forms a dimer in solution2, but both monomeric as dimeric survivin appear in 
vivo3. Although survivin biology is still complex, its bifunctional role in mitosis and apoptosis are 
well-recognized. 
SVV is of key importance during different stages of mitosis. This is reflected by (I) expression of the 
protein, which is cell cycle-dependent and peaks at G2/M4 and (II) the pleiotropic mitotic defects 
caused by SVV interference5-7. SVV is essential for chromosome alignment, sister chromatid 
segregation and cytokinesis5-7. Furthermore, SVV plays a central role during metaphase-anaphase 
transition, where the protein is required for sustained checkpoint activation in response to lack of 
microtubule tension or, in other words, when syntelic or merotelic attachments arise at metaphase5,6. 
SVV operates from two distinct subcellular pools in order to perform its different functions during 
mitosis. On the one hand, SVV binds mitotic spindle microtubules during metaphase, anaphase and 
late telophase4. Thereby, it suppresses microtubule dynamics3,8 and reduces centrosomal microtubule 
nucleation8. On the other hand, SVV forms a subunit of the chromosomal passenger complex (CPC), 
which is of vital importance for correct chromosome segregation and cytokinesis9,10. 
Mitochondrial SVV, but not cytosolic, exerts a cytoprotective effect11. Apoptotic stimuli induce rapid 
release of mitochondrial SVV in the cytosol, where it inhibits apoptosis by preventing activation or 
activity of initiator caspase-9 (caspase-dependent)3,11-15 or by restraining apoptosis-inducing factor in 
the mitochondrial intermembrane space (caspase-independent)3,15. 
SVV is highly expressed in most cancer types, compared to untransformed tissues1,16. Moreover, SVV 
expression in tumour cells is mainly cell cycle-independent, which indicates an increased anti-
apoptotic role of SVV17. This theory is further strengthened by the fact that only tumour cells harbour 
a cytoprotective mitochondrial pool of SVV. This pool is selectively expanded in response to cellular 
stress. In this way, cancer cells elevate the anti-apoptotic threshold and adapt to environmental stress11. 
High SVV expression also enhances tumour cell migration and invasion18, stimulates metastasis18,19 
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and maintains cancer stem cell integrity20, which are other hallmarks of carcinogenesis. Consequently, 
high SVV expression indicates poor prognosis and high tumour recurrence16 and is associated with 
chemo- and radiotherapy resistance21,22. 
SVV’s protuberant role in carcinogenesis and its differential expression in tumour versus 
untransformed tissue, instigated development of SVV-based cancer therapies23. Unfortunately, SVV 
biology remains extraordinarily complex and controversial24 and a better understanding of its 
biochemical pathways is vital for efficient design of personalized therapeutics23,24. 
We and others have used single-domain antibodies or nanobodies (Nbs or VHHs; Variable domain of 
Heavy chain of Heavy chain antibodies) as bona fide research tools to investigate protein function and 
to unravel biochemical pathways25-29. The unique biochemical and biophysical properties of 
nanobodies and their potential of targeting novel epitopes, render them superior to antibodies or 
antibody-fragments30,31. Moreover, nanobodies represent a complementary strategy to RNAi, as they 
can be used to study functions of structural (‘undruggable’) proteins32. Here, we present a SVV 
nanobody that binds SVV with high affinity and accurately tracks SVV during different phases of 
mitosis as intrabody, without perturbing its function. Moreover, equipping the nanobody with an 
appropriate delocalization tag successfully shuttles endogenous SVV towards different cell organelles 
(nucleus, mitochondria and peroxisomes). Our data demonstrate that this SVV nanobody is an 
excellent tool to further unravel the complex SVV topography and biology.  
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RESULTS 
Characterization of survivin nanobodies 
We identified 28 different nanobodies following phage display, belonging to 22 different groups 
according to their amino acid sequence. A phylogenetic tree confirms that nanobodies belonging to the 
same group (Nb21 and 19; Nb14, 11 and 26; Nb1, 15, 17 and 12) are derived from a common 
antecedent sequence and are thus clustered. (Fig. 1a). To assess antigen binding, recombinant HA-
tagged nanobodies were used to pull down endogenous survivin (SVV) from HeLa cells, which was 
successful for 22 out of the 28 nanobodies (Fig. 1b). All nanobodies were successfully expressed in 
the bacterial lysate. Nb2, 3, 4, 6, 7 and 16 were not able to bind endogenous SVV, although they were 
expressed to the same extent as positive, SVV-binding nanobodies. Of note, all non-binding 
nanobodies are clustered in the phylogenetic tree, except for Nb3 (Fig. 1a). Next, nanobodies were 
evaluated for their ability to function as intrabodies. To this end, transiently expressed EGFP-tagged 
nanobodies were assessed for their target binding in HEK293T cells by means of co-
immunoprecipitation (Fig. 1c). All nanobodies were successfully expressed intracellularly and 17 out 
of the 28 nanobodies (Nb 8-15, 17, 19-22, 24-25, 27-28) were able to recognize endogenous SVV in 
the complex eukaryotic environment, although to a different extent. Figure 1a gives an overview of the 
expression and binding characteristics of the 28 SVV nanobodies. Recombinant nanobodies that do 
not bind SVV, also do not function as an intrabody. Notably, the branch at the far right of the 
phylogenetic tree only contains nanobodies that do not bind intracellularly (Fig. 1a), except for Nb28 
(which binds SVV to a low extent). The following nanobodies were categorized as strong intracellular 
binders: Nb8-11, Nb14-15, Nb19, Nb22 and Nb27. 
 
SVVNb8 binds full-length SVV with high affinity 
We performed a detailed biochemical characterization of survivin nanobody 8 (SVVNb8), which 
strongly binds SVV both in vitro and in vivo. The epitope to which SVVNb8 binds was determined by 
means of GST-pull-down experiments (Fig. 2a). SVV consists of two domains: an N-terminal BIR 
domain linked to a C-terminal α-helix. A dimer interface domain (D) precedes the BIR domain and 
separates it from the α-helix24. SVVNb8 only binds with full-length SVV, not the distinct SVV 
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domains. This suggests that the nanobody recognizes (I) a linear epitope or conformational epitope 
which includes both domains or (II) a conformational epitope on one domain whose structure is lost 
when another domain is missing. As SVVNb8 could not detect denatured endogenous SVV on 
Western blot, we can confirm that the nanobody binds a conformational epitope (Fig. 2b). 
Subsequently, the binding affinity and stoichiometry of the SVVNb8 to GST-SVV binding were 
determined using isothermal titration calorimetry (Fig. 2c). A Kd value of 0.95 ± 0.53 nM and a molar 
ratio of 2 SVVNb8s to 1 GST-SVV could be derived. A reaction stoichiometry of 2:1 implies that 
GST-SVV forms a dimer in solution, which is confirmed by native PAGE (Fig. 2d). Dimerization is 
likely to be caused in part by the GST-tag and in part by SVV itself2, as cortactin (a true monomeric 
protein of 85 kDa33) also appears in two discrete bands when coupled to a GST-tag, as does His6-SVV 
(without GST-tag). In conclusion, SVVNb8 recognizes a conformational epitope and binds full-length 
SVV with high affinity (Kd= ~1 nM). 
 
A SVVNb8 intrabody accurately tracks SVV during different phases of mitosis 
SVV plays a key role during different phases of mitosis as a member of the chromosomal passenger 
complex (CPC)10. This is reflected by the presence of the protein in the spindle midzone and midbody 
in HeLa cells during late anaphase and telophase respectively (Fig. 3a). Upon SVVNb8 expression, 
the nanobody signal colocalizes with SVV at the spindle midzone and midbody (Fig. 3b, arrowheads). 
SVVNb8 is also enriched between sister chromatids and at cell poles (Fig. 3b, arrows), while this is 
not the case for the commercial antibody (Fig 3a). SVV RNAi completely abolishes this SVVNb8 
pattern (see Supplementary Fig. S1 online). Subsequently, we investigated if SVVNb8 impedes the 
interaction of SVV with the chaperone Hsp90AA1, which is necessary for SVV stability34. SVVNb8 
did not interfere with the SVV/Hsp90AA1 interaction and co-precipitated with the complex in MDA-
MB-231 cells (Fig 3c). SVV stability in SVVNb8 presence is supported by the fact that we did not 
observe aberrant cell division in SVVNb8-expressing cells (Fig. 3b). Moreover, XTT cell viability 
assays show that SVVNb8-EGFP expression does not have a significant effect on cell viability when 
compared to an EGFP-control (p= 0.40) (Fig. 3d). In brief, we conclude that SVVNb8 accurately 
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traces SVV at the CPC during late anaphase and telophase and does thereby not affect cell division or 
cell viability. 
 
SVVNb8 efficiently delocalizes endogenous SVV towards various cell organelles 
Nuclear export and import 
To further ascertain the efficacy of SVVNb8 as intrabody and explore its ability to bind and relocalize 
its target to different cellular compartments, we coupled EGFP-SVVNb8 C-terminally with a nuclear 
export signal (NES) or nuclear localization signal (NLS). The signal sequences are derived from the 
NES of MAPKK35 and the NLS from the Simian virus 40 large T antigen36, respectively (see 
Supplementary Table S1 online). SVVNb8 and SVV are homogenously distributed throughout HeLa 
cancer cells during interphase and to some extent enriched at the nucleus (Fig. 4a). Tagging with NES 
or NLS delocalizes both the control CapG nanobody and SVVNb8 to the cytoplasm (Fig 4b, left 
panels) or nucleus (Fig. 4c, left panels), respectively. Only SVVNb8 is however able to achieve SVV 
nuclear export or import (Fig. 4b and c, middle panels). We already reported successful CapG 
delocalization towards the nucleus or cytoplasm by CapGNb4-NLS or CapGNb4-NES, respectively25. 
Thus, NES and NLS-tagged SVV intrabodies are able to efficiently guide the SVV pool out, or into 
the nucleus, respectively. 
 
Mitochondrial membrane anchoring 
We next set out to immobilize endogenous SVV at the outer mitochondrial membrane or in the inner 
mitochondrial space. To this end, an N-terminal mitochondrial outer membrane (MOM) or mitofilin-
tag was coupled to V5-tagged SVVNb8. The MOM-tag originates from yeast TOM7037 while the 
mitofilin-tag is derived from human mitofilin38 (Supplementary Table S1). SVVNb8 is normally not 
enriched at Mitotracker-labelled mitochondria of HeLa cells, but is ubiquitously distributed together 
with SVV with slight enrichment at the nucleus (Fig. 5a). Conversely, tagging nanobodies with a 
MOM or mitofilin sequence efficiently redirects both control GFP nanobody and SVVNb8 towards 
mitochondria (Fig. 5b). Moreover, SVV does not adopt a mitochondrial-like pattern in MOM-GFPNb 
expressing control cells, while MOM or mitofilin-tagged SVVNb8 clearly relocalizes SVV (Fig. 5c). 
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Confocal microscopy allowed a more detailed investigation of this SVV-MOM/mitofilin-SVVNb8 
mitochondrial recruitment (See Supplementary Fig. S2 online). MOM-SVVNb8 and relocalized SVV 
typically encircle the mitochondrial pattern and the same applies to mitofilin-SVVNb8 with SVV. 
Examination of the intensity profiles over the mitochondria confirms this characteristic outer rim 
enrichment of the nanobody and SVV, as their intensity peaks at the edges of the Mitotracker peak. In 
conclusion, MOM and mitofilin-tagged SVV intrabodies are able to efficiently capture endogenous 
SVV at mitochondria and both accumulate at the outward mitochondrial area. A schematic 
representation of the mitochondrial recruitment assay is depicted in Supplementary Figure S2. 
 
Peroxisomal matrix transport 
Finally, SVVNb8 was coupled to a consensus sequence of the type I peroxisomal targeting sequence 
(PTS1)39, with the purpose of shuttling the nanobody to the peroxisomal matrix (Supplementary Table 
S1). The fluorescence signal of PTS1-tagged control GFPNb-V5 and SVVNb8-V5 adopts a dotted 
pattern in PC-3 prostate cancer cells, which colocalizes with the peroxisome markers PMP70 (Fig. 6a) 
and Pex14p (Fig. 6b). This indicates that both nanobodies are transported towards the peroxisomes. 
Colocalization between the nanobody signal and SVV in a dotted pattern only occurs upon PTS1-
tagged SVVNb8 expression (Fig. 6c). In contrast, SVV is virtually ubiquitous in the control PTS1-
tagged GFPNb cells, where it resides in the nucleus as well as in the cytoplasm.  
Of note, peroxisomal transport of the nanobodies is Pex5p-dependent, since Pex5p-deficient 
fibroblasts only succeed in nanobody transport when the Pex5p import receptor is co-expressed (see 
Supplementary Fig. S3 online). Consequently, Pex5p expression induces a speckled SVV pattern in 
Pex5p-deficient fibroblasts, which colocalizes with SVVNb8 and Pex5p. This suggests that the 
complete SVV-SVVNb8 complex is transported to the peroxisomes by means of the PTS1-tag and that 
this process is Pex5p-dependent. 
 
Next, stable PC-3 cell lines with doxycycline-inducible GFPNb-V5/PTS1 or SVVNb8-V5/PTS1 
expression were generated. This allows fine-tuning of nanobody expression and consistent expression 
levels, which increases reproducibility. No expression leakage was observed in the stable cell lines and 
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maximal expression is achieved by incubation with 500 ng/ml doxycycline (Dox) (Fig. 7a). We 
evaluated the amount of SVV and PTS1-tagged nanobody expressed in the latter condition by 
comparing different amounts of crude lysate with recombinant standards (Fig. 7b). GFPNb-PTS1 is 
approximately six times more expressed than endogenous SVV and there are roughly equal amounts 
of SVVNb8-PTS1 and SVV. Similarly as in transiently transfected cells, the PTS1-tagged nanobodies 
colocalize with the peroxisome marker PMP70 (Fig. 7c) and only SVVNb8-PTS1 relocates 
endogenous SVV (Fig. 7d).  
 
Peroxisomal transport was investigated in more detail by confocal microscopy and intensity profiles 
along peroxisomes in these stable cell lines. Concerning the integral peroxisomal membrane protein 
PMP70, the margins of the intensity profile reveal a more expanding PMP70 signal compared to the 
nanobody signal and both peak simultaneously (Fig. 8a). This suggests that the PTS1-tagged 
nanobodies are localized under, or at least at, the peroxisomal membrane. Secondly, the signal of the 
genuine peroxisomal matrix protein catalase starts, peaks and ends concurrently with the nanobody 
signal along the peroxisome (Fig. 8b). Thus, the nanobody will likely be in, or at least in close 
proximity of, the peroxisomal matrix. Finally, the signal intensity course for SVV and PTS1-tagged 
SVVNb8 is identical (Fig. 8c), suggesting SVV relocalization towards places of nanobody enrichment. 
A schematic representation of the peroxisomal transport assay is depicted in Figure 8d.  
In summary, coupling SVVNb8 to the peroxisomal matrix targeting sequence PTS1 was sufficient to 
successfully delocalize the nanobody and SVV towards peroxisomes in a Pex5p-dependent manner. 
Moreover, confocal microscopy suggests peroxisomal import of the PTS1-tagged SVVNb8 and a 
redistribution of SVV towards this location.
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DISCUSSION 
In this study, we have generated a SVV nanobody (SVVNb8) that binds SVV with high affinity. 
Expressed as intrabody, SVVNb8 correctly tracks SVV during different phases of mitosis, without 
interfering with SVV function. Furthermore, coupling SVVNb8 with a delocalization tag efficiently 
delocalizes endogenous SVV towards the nucleus and peroxisomes, and captures SVV at 
mitochondria. Based on our findings, we believe that SVVNb8 is an excellent tool to further elucidate 
SVV biology and topography. 
Although Nb2, 3, 4, 6, 7 and 16 were successfully expressed recombinantly, they were not able to bind 
endogenous SVV (Fig. 1a and b). These nanobodies likely recognize an epitope encompassing His6 
and SVV, or bind SVV with very low affinity. Nb1, 5, 18, 23 and 26 bind their target when 
recombinantly expressed, but not as an intrabody (Fig. 1). This is quite exceptional in our experience. 
Possibly, these nanobodies suffer from the reducing intracellular environment, which may 
theoretically lead to reduction of disulphide bridges, partial unfolding and thereby loss-of-function. 
SVVNb8 most likely detects a conformational epitope on SVV, as the nanobody cannot detect 
denatured SVV on blot (Fig. 2b). Similarly, L-plastin nanobodies bind conformational epitopes and 
also failed to detect denatured L-plastin32. By contrast, a nanobody against gelsolin (gelsolin Nb13) 
recognizes a linear linker between two gelsolin subdomains and can be used as a detection tool in 
Western blot40. 
SVV function is of key importance during different stages of mitosis4-7. The subcellular localization of 
SVV during mitosis has been contentious, as researchers only detected a pool of SVV associated with 
tubulin (microtubule and centrosomes)4, or a pool of SVV associated with the chromosomal passenger 
complex (CPC)9 in vivo. We found that intrabody SVVNb8 was enriched at the central spindle 
midzone and midbody during late anaphase and telophase (Fig. 3b, arrowheads), which is reminiscent 
of the CPC pattern. Moreover, SVVNb8 was enriched at cell poles and between sister-chromatids in a 
threadlike pattern, presumably detecting microtubule and centrosome-associated SVV (Fig. 3b, 
arrows). The microtubule-associated SVV staining is however rather blurry, which could be explained 
by the fact that (I) we did not stabilize microtubules during immunostaining4,41 and (II) SVVNb8 is 
highly expressed. The latter can be solved by using inducible stable cell lines where nanobody 
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expression can be fine-tuned (cf. Fig. 7). SVV RNAi confirms SVVNb8 specificity as the typical 
SVVNb8 pattern disappears when SVV siRNA is expressed (Supplementary Fig. S1). Since SVVNb8 
intrabody labels both SVV subpopulations, we conclude that the nanobody acts as a faithful SVV 
tracer. This is in line with one of our previous reports on nuclear transport factor 2 (NTF2) 
nanobodies, where we were able to reveal a new location of NTF2 at the centrosome42. Recently, 
fluorescently labelled anti-tubulin nanobodies were used to visualize microtubules in super-resolution 
microscopy. Nanobodies are 10× smaller compared to conventional antibodies and accordingly, the 
distance between fluorophore and target is significantly reduced. In this way, individual microtubules 
could be visualized43. As SVVNb8 reliably binds its target, we believe that SVVNb8 is a potential 
candidate to visualize endogenous SVV in super-resolution microscopy. 
Interference with SVV expression or function causes an increase in apoptosis5,7,44, particularly in cells 
approaching mitosis44. The apoptotic response results from mitotic catastrophe, caused by multiple 
mitotic defects after SVV knock down7. Here, we show that SVVNb8 expression does not affect cell 
division or cell viability (Fig. 3b and d), which implicates that the nanobody does not interfere with 
SVV function during mitosis. Moreover, we presume that SVV protein stability is preserved in the 
presence of SVVNb8, as the nanobody does not inhibit SVV to interact with its chaperone Hsp90AA1 
(Fig. 3c). We and others have already used nanobodies in live cell imaging, to study endogenous 
antigen localization in vivo28,45-47. Based on these observations, we believe that SVVNb8 can be a good 
tracer for endogenous SVV in live cell imaging to further investigate the complex topography of the 
protein.  
The epitope of SVVNb8 could not be pinpointed, but our results suggest that the BIR-domain (without 
the Hsp90AA1-interacting residues K79-K9034) is involved. The α-helix and dimer interfaces are 
involved in extensive protein-protein interactions required for proper SVV function during mitosis 
(tubulin binds the α-helix 2,4, CPC members Borealin and INCENP bind the α-helix and dimer 
interfaces10,48), which is not hampered when expressing the nanobody intracellularly. Furthermore, 
SVVNb8 does not interfere with SVV dimerization (Fig. 2c), which requires the dimer interfaces2. As 
SVVNb8 did not recognize BIR or BIR-dimer interfaces in a GST-pull down epitope mapping (Fig. 
2a), the conformation of the epitope is probably altered in truncated SVV. 
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We equipped intrabody SVVNb8 with different delocalization tags in order to demonstrate nanobody 
functionality in vivo and to manipulate endogenous SVV localization. The preferential site for 
nanobody fusion is C-terminal, as this is the natural connection site for the constant domain. In 
addition, nanobody paratope clusters at the N-terminal end30; adding a delocalization tag therefore 
potentially interferes with antigen binding. Here we show that SVVNb8 retains its antigen binding 
activity upon fusion of N-terminal tags (mitofilin or MOM), as SVV faithfully follows the location of 
tagged SVVNb8 (Fig. 5c and Supplementary Fig. S2). 
Tagging SVVNb8 with a MOM or mitofilin tag is sufficient to delocalize the nanobody towards the 
mitochondria (Fig. 5b and Supplementary Fig. S2) and induces mitochondrial enrichment of SVV 
(Supplementary Fig. S2). Intensity profiles confirm MOM/mitofilin-SVVNb8 and SVV accumulation 
at the outer rim of the mitochondria (Supplementary Fig. S2), but limited Mitotracker and/or confocal 
microscope resolution does not allow distinction between outer membrane (MOM-delocalization) or 
inner membrane (mitofilin-delocalization) anchored SVV-SVVNb8-complex. In other words, unlike 
the peroxisomal transport assay, we are unable to exactly pinpoint the location of the protein complex 
based on the intensity profiles (Supplementary Fig. S2). Mitotracker is expected to accumulate at the 
mitochondrial matrix, where it covalently binds free thiol groups49. We assume that the dye partially 
reacts with proteins in the intermembrane space and/or at the outer membrane, resulting in a less well-
defined Mitotracker signal. Moreover, it is not possible to distinguish inner from the outer 
mitochondrial membrane when using a confocal microscope. Nevertheless, John and co-workers 
reported successful mitochondrial import of proteins coupled to amino acids 1-187 (containing the 
mitochondrial targeting and membrane anchor domain) of mouse mitofilin38. We believe that this 
mitochondrial recruitment assay, using mitofilin-tagged nanobodies, can be used as a model to study 
mitochondrial protein import. 
Unlike mitochondria and endoplasmic reticulum, peroxisomes are capable of importing oligomeric 
protein complexes50-55, although the physiological relevance of oligomeric import has been 
questioned55. Nevertheless, our results strongly suggest peroxisomal import of a protein complex and 
therefore support previous findings. Since SVVNb8-PTS1 is likely imported into the peroxisomes 
(Fig. 8a and b, intensity profiles) and the SVVNb8-PTS1 signal colocalizes with the SVV signal (Fig. 
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8c, intensity profile), we expect that SVV is also imported into peroxisomes. We also confirm that 
tagging one of two interacting proteins with PTS1 is sufficient to mediate import of the other50-55. 
 
Altogether, these findings show that we can manipulate endogenous SVV location using tagged 
SVVNb8. Delocalization can be an elegant strategy to perturb protein function by limiting free 
diffusion in cells and restricting protein availability at places where it is needed42,56. For instance, 
tumour cells harbour a mitochondrial pool of SVV which, in contrast to cytosolic SVV, protects cells 
from caspase-dependent and independent apoptosis3,11-15,57. Mitofilin-SVVNb8 could be used to further 
study the anti-apoptotic function of mitochondrial SVV. When mitochondrial SVV is immobilized at 
the inner membrane, we predict that it can no longer participate in the cytoprotective response and 
tumour cells are expected to become more sensitive to apoptotic stimuli. 
Hypothetically, protein delocalization can also be technically applied in organellar proteomics, in 
order to tackle high background when identifying protein interaction partners. Organellar proteomics 
implicates subcellular fractionation of the organelle of interest before mass spectrometry, which 
eliminates potentially contaminating cytoplasmic proteins. Sample complexity is therefore compatible 
with the sensitivity of current mass spectrometers and allows identification of low abundance 
proteins58. Supposing SVV is imported into peroxisomes by means of SVVNb8-PTS1, we could 
potentially detect SVV interaction partners by organellar proteomics. Furthermore, protein catalogues 
of peroxisomes are available59,60, which makes it possible to discern bona fide peroxisomal proteins 
from SVV binders. Of note, we do not know the size limitations of the peroxisomal import machinery. 
It is possible that this technique is not suitable for large protein complexes, as import would be 
ineffective or impossible. Nonetheless, it is worth mentioning that tetrameric catalase, with a 
molecular weight of 240 kDa, was successfully imported into the peroxisomal matrix50. 
In summary, we show that SVVNb8 is a versatile and excellent tool to further sort out the complex 
SVV biology and topography. Moreover, we believe that this nanobody technology presented here can 
be easily extrapolated to other (structural) proteins. 
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METHODS 
Generation of survivin (SVV) nanobodies 
See Supplementary Methods for details on the generation of survivin-specific nanobodies. 
 
cDNA cloning 
See Supplementary Methods for a detailed description on the cloning reactions. 
 
Antibodies 
See Supplementary Methods for a detailed description on the antibodies used in this study. 
 
Production and purification of recombinant SVV nanobodies, GST-SVV, GST-SVV fragments, 
GST-cortactin and His6-SVV 
See Supplementary Methods for details on recombinant protein expression and purification. 
 
SVV RNAi 
See Supplementary Methods for a detailed description on the SVV RNAi experiment. 
 
Cell culture, transfection and transduction 
HeLa, HEK293T, MDA-MB-231 and PC-3 cells were grown at 37 °C in a humidified 10% CO2 
incubator. Pex5p-deficient fibroblasts (Zellweger cells) were a kind gift of Prof. Dr. Ronald Wanders 
(Department of Clinical Chemistry, Academic Medical Centre, University of Amsterdam, The 
Netherlands) and were maintained at 37 °C and 5% CO2. All cells were cultured in DMEM, PC-3 cells 
were cultured in RPMI (media from Gibco, Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 10% foetal bovine serum. Transient transfection was generally achieved with 
jetPRIME (Polyplus Transfection Inc., New York, NY, USA). HEK293T cells were transfected using 
the calcium phosphate method. Transfection in Pex5p-deficient fibroblasts was performed using the 
Neon Transfection System (Thermo Fisher Scientific). Cells were either sequentially transfected 
(Pex5p-FLAG transfection 48 h after nanobody transfection) or cotransfected. 
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PC-3 cells stably expressing GFPNb-V5-PTS1 or SVVNb8-V5-PTS1 were created using the Lenti-X 
Tet-On Advanced Inducible Expression System (Clontech) as previously described56. In brief, 
HEK293T were calcium phosphate-transfected with packaging (psPAX2), envelope (pMD2.G) and 
nanobody (pLVX-Tight-Puro) plasmids. Medium with lentiviral particles was collected 48 h and 72 h 
post-transfection, filtered (0.45 µm) and concentrated by means of ultracentrifugation. Viral titre was 
determined by crystal violet staining on transduced and puromycin (nanobody) or G418 (regulator) -
selected HEK293T cells. Next, PC-3 cells were infected at an MOI=5 with regulator and nanobody 
virus and subjected to puromycin and G418 selection for 2 weeks. 
 
Assessing SVV nanobody binding characteristics 
Pull-down and co-immunoprecipitation assays 
HeLa, MDA-MB-231 or transfected HEK293T cells were lysed with ice-cold lysis buffer (0.5% NP-
40, 1 mM PMSF and 1 mM protease inhibitor cocktail in PBS), sonicated and pelleted. Protein 
concentrations were determined using the Bradford assay (Bio-Rad Laboratories, Hercules, CA, 
USA). For the pull-down experiment, recombinant HA-tagged nanobodies from periplasmic extract 
were immobilized onto HA-agarose beads (Sigma-Aldrich, St. Louis, MO, USA) (1-2 h at 4 °C), 
followed by incubation with 1 mg crude HeLa lysate (1 h at 4 °C). For the SVV-nanobody co-
immunoprecipitation experiment, EGFP-tagged intrabodies from 1 mg HEK293T lysate were 
immobilized onto anti-GFP antibody (1-2 h at 4 °C), followed by coupling to protein G sepharose 
beads (GE Healthcare) (1 h at 4 °C). For the SVV-Hsp90 co-immunoprecipitation experiment, 1 mg 
crude MDA-MB-231 lysate was pre-incubated with 5 µg purified GFPNb-His6/STREP or SVVNb8-
His6/STREP for 1 h at 4 °C, followed by incubation with anti-SVV antibody (D-8) and protein G 
sepharose beads (GE Healthcare) (1 h each at 4 °C). After washing, beads were eluted by boiling in 
Laemmli SDS sample buffer (65 mM Tris-HCl pH 6.8, 20% glycerol, 5% SDS, 0.2% bromophenol 
blue, 5% β-mercaptoethanol in Milli-Q), followed by SDS-PAGE and Western blot analysis. Ab469 
was used to detect SVV on blot. 
 
Epitope mapping  
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Glutathione beads coated with GST-fusion proteins were incubated with 10 µg purified recombinant 
SVVNb8-V5/SBP/His6 in wash buffer (0.5% Triton X-100, 1 mM PMSF and 1 mM protease inhibitor 
cocktail in PBS) during 2 h at 4 °C. Beads were recovered by centrifugation and the samples were 
subsequently washed, boiled, fractionated by SDS-PAGE and visualized by Coomassie Blue staining. 
 
Nanobody-mediated detection of endogenous SVV on Western blot  
Equal amounts of HEK293T, HeLa and PC-3 lysates were analysed using SDS-PAGE and blotted 
onto a nitrocellulose membrane. After 1 h in blocking solution (5% non-fat dry milk in 100 mM Tris 
pH 7.5, 1.5 M NaCl and 1% Tween (TBS-T)), the membranes were incubated with 5 µg/ml purified 
SVVNb8-His6/STREP, 5 µg/ml purified GFP Nb-His6/STREP or 1 µg/ml commercial SVV antibody 
(ab469) (overnight, at 4 °C). Bound His6-tagged nanobody was detected by subsequent incubation 
with anti-His6 antibody and anti-mouse HRP-coupled antibody (1 h incubation each at room 
temperature). Detection of the commercial anti-SVV antibody was performed using anti-rabbit HRP-
coupled antibody (1 h at room temperature). 
 
Isothermal titration calorimetry 
The binding affinity of SVVNb8-His6/STREP to GST-SVV was determined by isothermal titration 
calorimetry, using a Microcal VP-ITC MicroCalorimeter (Malvern Instruments Ltd, Malvern, UK) as 
previously described40. 45 µM purified SVVNb8-His6/STREP was gradually titrated within the sample 
cell containing 4.5 µM GST-SVV, after dialysis against 20 mM Tris pH 7.5, 150 mM NaCl. Heat 
release was registered per SVVNb8-His6/STREP injection in function of time. Each peak was 
integrated and plotted versus the molar ratio of SVVNb8-His6/STREP to GST-SVV. The ITC data was 
fitted to a ‘One Set of Sites’ model using the Microcal Origin software, from which the affinity and 
stoichiometry of the reaction could be derived. 
 
XTT assay 
Equal amounts of HeLa cells were seeded in a 96-well plate and transiently transfected with EGFP 
only or EGFP-tagged SVVNb8. 24 h post-transfection, an XTT assay (XTT cell proliferation kit II, 
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Roche) was performed according to the manufacturer’s instructions. Briefly, 50 µl of XTT labelling 
mixture was added to each well. At time points 0 h and 4 h, absorbance was measured at 450 nm 
(Aformazan) and 620 nm (Abackground). Background absorbance was subtracted from formazan absorbance 
at each time point. Net absorbance (A4 h – A0 h) is proportionate to the amount of metabolically active 
cells. The effect of each construct was studied three times in three independent experiments. A Mann-
Whitney Rank Sum Test (ordinal and independent observations which are not normally distributed; n= 
3, pEGFP-N1 versus SVVNb8-EGFP transfected cells, α= 0.05, two-tailed) was used to analyse the 
results via Sigmaplot (Systat Software Inc., San Jose, CA, USA). 
 
Native PAGE 
0.5 µg recombinant His6-SVV, GST-SVV and GST-cortactin in native sample buffer (Laemmli SDS 
sample buffer without SDS and β-mercaptoethanol) was loaded on top of a 15% or 6% native 
polyacrylamide gel, which lacks SDS. Protein mono- and oligomers were analyzed by Western blot. 
 
Immunofluorescence and microscopy 
Coverslips were coated with 50 µg/ml rat tail type I collagen (BD Biosciences, Franklin Lakes, NJ, 
USA) in PBS (with Ca2+ and Mg2+) for 1 h at 37 °C. Cells were seeded onto the coated coverslips at a 
density of 60-80%. 24 h post-seeding, cells were transfected with nanobody-plasmid or nanobody 
expression was induced by adding doxycycline to a final concentration of 500 ng/ml, unless 
mentioned otherwise. Immunostaining was performed 24 h later. Pex5p-deficient fibroblasts were 
seeded onto collagen-coated coverslips directly after Neon transfection. Visualization of mitochondria 
was achieved by incubating living cells with 0.1 µM Mitotracker Orange (M-7510, Thermo Fisher 
Scientific) in cell-specific serum-free medium for 30 min at 37 °C. Cells were fixed with 3% 
paraformaldehyde for 25 min, permeabilized 5 min with 0.2% Triton X-100 and additionally 
incubated with 0.75% glycine for 20 min. Every incubation step was followed by at least three 
washing steps. After blocking in 1% bovine serum albumin (BSA), coverslips were incubated with 
primary and secondary antibodies (resp. 1 h at 37 °C and 30 min at room temperature, both diluted in 
1% BSA). Antibody incubation steps were separated by four 4 min wash steps in 1% BSA. Nuclei 
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were stained with 0.4 µg/ml DAPI (D9542, Sigma-Aldrich) during the last antibody incubation step. 
Finally, cells were washed twice. PBS with Ca2+ and Mg2+ was used for all dilutions and washing 
steps, unless mentioned otherwise. All SVV-immunostainings were performed using ab469. 
Coverslips were mounted onto microscope slides using Vectashield antifade mounting medium 
(Vector Laboratories, Burlingame, CA, USA) and were sealed with nail polish. Cells were analyzed at 
room temperature using a Zeiss Axiovert 200M fluorescence microscope with Apotome module (Zeiss 
x63 1.4-NA Oil Plan-Apochromat objective, Carl Zeiss, Oberkochen, Germany) and Axiovision 4.5 
software (Zeiss) or an Olympus IX81 Fluoview 1000 confocal laser scanning microscope (Olympus 
x60 1.36-NA Oil UplanSApo objective, Olympus, Tokyo, Japan) with FluoView FV 1000 software 
(Olympus). Intensity profiles were generated by means of ImageJ (National Institutes of Health, 
Bethesda, MD, USA). 
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FIGURE LEGENDS 
Figure 1. Validation and characterization of SVV nanobodies. a. Phylogenetic tree of 28 SVV 
nanobodies representing their interrelations. The nanobodies can be classified into 22 different groups 
according to their amino acid sequence, of which 3 groups (depicted by horizontal solid lines) contain 
several members.  represents non-functional recombinant nanobodies. Unlabelled nanobodies bind 
SVV recombinantly. Nanobodies were additionally classified according to their intracellular binding 
capacity. This results in the following candidates for further use: Nb8-11, Nb14-15, Nb19, Nb22 and 
Nb27. b. Pull-down experiment of endogenous SVV from HeLa cervix cancer cell lysate with 
recombinant HA-tagged nanobodies by means of anti-HA agarose beads. A negative control was 
included using HeLa cell lysate with anti-HA agarose beads only (C1). Cells expressing CapGNb2, a 
nanobody targeting the capping protein CapG, were used as a negative control (C2). Nanobodies were 
blotted with anti-HA antibody. CL= crude lysate. Full-length blots are presented in Supplementary 
Figure S4 online. c. Immunoprecipitation experiment of endogenous SVV in HEK293T cells 
transfected with EGFP-tagged nanobodies, by means of an anti-EGFP antibody. Two negative controls 
were included using cell lysates with EGFP only (C1) or CapGNb4-EGFP expression (C2). An anti-
GFP antibody was used to visualize the nanobodies. LC= light chain, HC= heavy chain of the anti-
GFP antibody. CL= crude lysate. * Depicts breakdown products of the EGFP-tagged nanobody 
construct. Full-length blots are presented in Supplementary Figure S4. 
 
Figure 2. Detailed binding characterization of SVVNb8. a. Epitope mapping experiment with GST 
only (control), GST-tagged full-length SVV (1), the BIR domain without (2) or with (3) dimer 
interfaces or the α-helix domain (4) as depicted at the left. The right upper panel shows the different 
recombinant GST fusion proteins. A Coomassie-stained gel of the GST-pull down experiment is 
shown in the right lower panel. SVVNb8 (*) can only be found together with full-length SVV. b. 
Representative blot on lysates of HEK293T, HeLa cervix cancer or PC-3 prostate cancer cells using 
recombinant His6/STREP-tagged SVVNb8 as Western blot reagent followed by an anti-His6 antibody. 
A commercial polyclonal anti-SVV antibody (ab469) and a His6/STREP-tagged GFP-targeting 
nanobody were used as positive and negative control, respectively. SVVNb8 does not detect SVV on 
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Western blot. Full-length blots are presented in Supplementary Figure S4. c. ITC profile of 
recombinant His6/STREP-tagged SVVNb8 (injected) with recombinant GST-SVV (sample cell). The 
upper panel shows raw data of heat release as a function of time, while the lower panel shows the 
fitted binding curve of total heat release per injection as a function of the molar ratio. SVVNb8 binds 
SVV with an affinity of Kd= 0.95 ± 0.53 nM and a molar ratio of 2:1 SVVNb8:SVV. d. Western blot 
after native PAGE of recombinant purified His6-SVV, GST-SVV and GST-cortactin. GST-cortactin 
was used as a control and native proteins were detected with anti-SVV (left and middle) or anti-
cortactin (right) antibody. Both His6-SVV and GST-SVV can form dimers in solution. * depicts 
monomeric protein, ** depicts dimeric protein. 
  
Figure 3. SVVNb8 colocalizes with SVV in different cell cycle stages without affecting cell 
viability. a. Endogenous SVV is typically enriched at the spindle midzone and the midbody between 
anaphase and cytokinesis, as visualized in HeLa cervix cancer cells (arrowheads ). b. HeLa cervix 
cancer cells transfected with a GFP-targeting nanobody (control) show no enrichment at the spindle 
midzone (first panel) or midbody (second panel). On the other hand, SVVNb8 is enriched at the 
spindle midzone (third panel) or midbody (lower panel) upon expression (boxed areas, arrowheads ). 
Boxed areas are enlarged in the insets. SVVNb8 is also enriched between sister chromatids and at the 
cell poles (arrows →) during late anaphase. Nuclei were visualized by means of DAPI and nanobodies 
with anti-V5 antibody. c. Representative co-immunoprecipitation experiment of endogenous 
Hsp90AA1-SVV complex in MDA-MB-231 breast cancer cells by means of anti-SVV antibody (D-8) 
coupled on protein G sepharose beads. A negative control was included using cell lysate with protein 
sepharose beads only (lane 3), representing the level of aspecific SVV binding on naked beads. Crude 
lysates were incubated with GFPNb (lane 1) or SVVNb8 (lane 2) prior to antibody-mediated SVV 
pull-down, or no nanobody was added (lane 4, positive control). Hsp90AA1 only co-precipitates when 
beads are specifically enriched for SVV (lane 4). SVVNb8 does not affect the interaction between 
Hsp90AA1 and SVV (lane 2), nor does GFPNb (lane 1). Only SVVNb8 co-precipitates with the 
complex (lane 2). Lane 5 and lane 6 contain 1 µg of GFPNb and SVVNb8, respectively. An anti-His6 
antibody was used to visualize the nanobodies. Longer exposure time was needed to detect SVV and 
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Hsp90AA1 in crude lysate (CL) than in other conditions. Full-length blots are presented in 
Supplementary Figure S4. d. XTT cell viability assay on HeLa cells transiently expressing EGFP 
(control) or SVVNb8-EGFP. Graphs represent mean net absorbance of formazan dye (dotted line) 
with range (three times three independent measurements; n= 3). P0.05-value was determined by a 
Mann-Whitney Rank Sum Test. SVVNb8-EGFP expression does not significantly alter cell viability 
compared to EGFP expression (p= 0.40). 
 
Figure 4. SVVNb8 redirects endogenous SVV in and out of the nucleus. Representative 
epifluorescence images of HeLa cervix cancer cells transiently expressing EGFP-tagged SVVNb8 
without (a) or with an nuclear export signal (b) or nuclear localization signal (c). CapGNb4 was used 
as a negative control. The nanobody and endogenous SVV are distributed over the whole cell body 
(a). The nuclear export signal (NES) excludes both nanobodies from the nucleus, with only SVVNb8-
NES resulting in delocalization of SVV (b). The nuclear localization signal (NLS) guides both 
nanobodies towards the nucleus, but only SVVNb8-NLS results in nuclear import of SVV (c). Nuclei 
are visualized with DAPI. 
 
Figure 5. SVVNb8 captures endogenous SVV at mitochondria. Representative epifluorescence 
images of HeLa cervix cancer cells transiently expressing SVVNb8 (a) equipped with a MOM or 
mitofilin-tag (b, c). MOM-tagged GFP nanobody was used as a negative control. The SVV nanobody 
and SVV are distributed throughout the cell without enrichment at the mitochondria (a). MOM or 
mitofilin-tagged control or SVV nanobodies become enriched at the mitochondria, labelled with 
Mitotracker (b). However, SVV only adopts a mitochondria-like pattern when MOM or mitofilin-
tagged SVVNb8 is expressed (c). Nuclei were visualized with DAPI and nanobodies with anti-V5 
antibody. Boxed areas are enlarged in the bottom right insets and arrowheads  indicate areas of 
colocalization. 
 
Figure 6. The PTS1-tagged nanobody redirects SVV towards the peroxisomes. Representative 
epifluorescence images of PC-3 prostate cancer cells transiently expressing PTS1-tagged GFP 
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nanobody (control) or SVVNb8. Both nanobodies colocalize with the peroxisomal markers PMP70 (a) 
and Pex14p (b). Only SVVNb8-V5/PTS1, but not the control nanobody, is able to induce SVV 
delocalization to a peroxisome-like pattern (c). Nuclei are visualized with DAPI and nanobodies with 
anti-V5 antibody. Boxed areas are enlarged in the bottom right insets and arrowheads  indicate areas 
of colocalization. 
 
Figure 7. Characterization of stable PC-3 cell lines with Dox-inducible expression of PTS1-
tagged GFP nanobody or SVVNb8. a. Representative epifluorescence images of stable PC-3 cells 
upon addition of 0 ng/mL, 10 ng/mL or 500 ng/mL Dox for 24 h showing inducibility and 
concentration-dependence of PTS1-tagged nanobody expression (left). Nuclei are visualized with 
DAPI and nanobodies with anti-V5 antibody. At the right, a Western blot is depicted, confirming 
inducibility and concentration-dependence of PTS1-tagged nanobody expression. Full-length blot is 
presented in Supplementary Figure S4. b. Determination of the amount of nanobody and endogenous 
SVV in the generated stable cell lines induced with 500 ng/mL Dox by comparing Western blot 
analysis on crude lysate (CL) with recombinant standards (His6-SVV and LPLNb5-V5, a nanobody 
targeting the actin-bundling protein L-plastin). Nanobodies were blotted with anti-V5 antibody. 
Arrowheads  indicate the estimated amount of protein corresponding to the level in the lysate, 
resulting in the ratios depicted at the bottom. Approximately six times more PTS1-tagged GFP 
nanobody is present compared to endogenous SVV. Conversely, PTS1-tagged SVVNb8 is expressed 
at an approximately 1:1 molar ratio to endogenous SVV. Full-length blots are presented in 
Supplementary Figure S4. c. Representative epifluorescence images of PC-3 prostate cancer cells 
stably expressing PTS1-tagged GFP nanobody (control) or SVVNb8 upon induction with 500 ng/mL 
Dox. Both the control and SVVNb8-V5/PTS1 colocalize with the peroxisomal marker PMP70. d. 
Only SVVNb8-V5/PTS1 is able to delocalize SVV towards the peroxisomes. Nuclei are visualized 
with DAPI and nanobodies with anti-V5 antibody. Boxed areas are enlarged in the bottom right insets 
and arrowheads  indicate regions of colocalization. 
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Figure 8. SVVNb8 localizes at the peroxisomal matrix and redistributes SVV accordingly. 
Representative confocal images of PC-3 prostate cancer cells expressing PTS1-tagged GFP nanobody 
(control) or SVVNb8 upon 24 h induction with 500 ng/mL Dox. Both the control and SVVNb8 
colocalize with the peroxisomal marker PMP70 (a), although PMP70 is additionally enriched at a 
region surrounding the nanobody. Colocalization studies with catalase on the other hand, reveal 
intensity overlap with the nanobody (b). Colocalization of SVV with the GFP nanobody does not 
occur, but is complete with the SVVNb8 (c). Nuclei are visualized with DAPI and nanobodies with 
anti-V5 antibody. Boxed areas are enlarged at the right. Graphs represent corresponding intensity 
profiles generated through the white solid lines. d. Schematic representation of the different 
components at the peroxisomes. PMP70 is a transmembrane protein and its signal colocalizes with and 
additionally surrounds the nanobody signal. Catalase on the other hand is an internal peroxisomal 
component and colocalizes completely with SVVNb8. SVVNb8 signal colocalizes with the SVV 
signal. 








